中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 6
Jun.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(6): 1268-1274

Current status of the research on low-level viremia in chronic hepatitis B patients receiving nucleos(t)ide analogues

DOI: 10.3969/j.issn.1001-5256.2021.06.007
  • 1.

    Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University, Beijing 100191, China

  • 2.

    Peking University Hepatology Institute, Peking University People's Hospital, Beijing 100044, China

  • 3.

    First Department of Liver Disease, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China

  • 4.

    Diagnosis and Treatment Center of Hepatic Fibrosis, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China

  • 5.

    Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China

  • 6.

    Department of Infectious Diseases & Liver Disease Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, China

  • 7.

    Institute for Viral Hepatitis, Chongqing Medical University, Chongqing 400060, China

  • 8.

    Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China

  • 9.

    Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China

  • 10.

    Infectious Diseases Center, Peking University First Hospital, Beijing 100034, China

  • 11.

    Department of Hepatology, The First Hospital of Jilin University, Changchun 130021, China

  • 12.

    Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, China

  • Received Date: 2021-05-04
  • Accepted Date: 2021-05-12
  • Published Date: 2021-06-20
    Abstract
  • Nucleos(t)ide analogues (NAs), which are widely used as the first-line anti-hepatitis B virus (HBV) drugs in clinical practice, can effectively inhibit the replication of HBV DNA, significantly slow down disease progression in chronic hepatitis B (CHB) patients, and reduce the development of end-stage liver diseases such as liver failure and liver cancer. However, for some CHB patients receiving first-line NAs for 48 weeks or longer, serum HBV DNA is still persistently or intermittently higher than the lower detection of limit of sensitive nucleic acid detection reagents. After discussion by the authors, low-level viremia (LLV) is defined as follows: persistent LLV refers to the condition in which CHB patients, who receive entecavir, tenofovir disoproxil fumarate, or tenofovir alafenamide fumarate for ≥48 weeks, have positive for HBV DNA are positive by two consecutive detections with sensitive quantitative PCR, with an interval of 3-6 months, but < 2000 IU/ml; intermittent LLV refers to serum HBV DNA are positive intermittently by at least three consecutive detections, with an interval of 3-6 months, but HBV DNA < 2000 IU/ml. For the diagnosis of LLV, the issues of poor compliance and drug-resistant mutations should be excluded. LLV might be associated with the increased risk of progression to liver fibrosis, or hepatocellular carcinoma in patients with liver cirrhosis under NA treatment, but there are still controversies over whether the original treatment regimen with NAs should be changed after the onset of LLV. This article summarizes the incidence rate of LLV under NA treatment and the influence of LLV on prognosis and analyzes the possible mechanisms of the osnet of LLV, so as to provide a reference for the management of LLV in patients treated with NAs.

     

    • FullText(HTML)
  • loading
    • References(55)
  • [1]
    REVILL PA, CHISARI FV, BLOCK JM, et al. A global scientific strategy to cure hepatitis B[J]. Lancet Gastroenterol Hepatol, 2019, 4(7): 545-558. DOI: 10.1016/S2468-1253(19)30119-0.
    [2]
    Chinese Society of Infectious Disease, Chinese Society of Hepatology, Chinese Medical Association. The expert consensus on clinical cure (functional cure) of chronic hepatitis B[J]. J Clin Hepatol, 2019, 35(8): 1693-1701. DOI: 10.3969/j.issn.1001-5256.2019.08.008.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎临床治愈(功能性治愈)专家共识[J]. 临床肝胆病杂志, 2019, 35(8): 1693-1701. DOI: 10.3969/j.issn.1001-5256.2019.08.008.
    [3]
    SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific Clinical Practice Guidelines on the management of hepatitis B: A 2015 update[J]. Hepatol Int, 2016, 10(1): 1-98. DOI: 10.1007/S12072-015-9675-4.
    [4]
    European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
    [5]
    TERRAULT NA, LOK A, McMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
    [6]
    KIM JH, SINN DH, KANG W, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment[J]. Hepatology, 2017, 66(2): 335-343. DOI: 10.1002/hep.28916.
    [7]
    YUEN MF, SETO WK, FUNG J, et al. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: Viral suppression, viral resistance, and clinical safety[J]. Am J Gastroenterol, 2011, 106(7): 1264-1271. DOI: 10.1038/ajg.2011.45.
    [8]
    LIU LJ, LIU Y, CHEN RJ, et al. Identification of a novel entecavir-resistant mutation rtL180M+A186T+M204V of hepatitis B virus[J]. Med J Chin PLA, 2019, 44(3): 197-202. DOI: 10.11855/j.issn.0577-7402.2019.03.02.

    刘璐洁, 刘妍, 陈容娟, 等. 乙型肝炎病毒新型恩替卡韦耐药突变rtL180M+A186T+M204V的鉴定[J]. 解放军医学杂志, 2019, 44(3): 197-202. DOI: 10.11855/j.issn.0577-7402.2019.03.02.
    [9]
    LIU Y, MILLER MD, KITRINOS KM. HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D[J]. Liver Int, 2014, 34(7): 1025-1032. DOI: 10.1111/liv.12343.
    [10]
    LU C, JIA Y, CHEN L, et al. Pharmacokinetics and food interaction of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy volunteers[J]. J Clin Pharm Ther, 2013, 38(2): 136-140. DOI: 10.1111/jcpt.12023.
    [11]
    European Association for The Study of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection[J]. J Hepatol, 2012, 57(1): 167-185. DOI: 10.1016/j.jhep.2012.02.010.
    [12]
    BUTI M, GANE E, SETO WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial[J]. Lancet Gastroenterol Hepatol, 2016, 1(3): 196-206. DOI: 10.1016/S2468-1253(16)30107-8.
    [13]
    CHAN HL, FUNG S, SETO WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial[J]. Lancet Gastroenterol Hepatol, 2016, 1(3): 185-195. DOI: 10.1016/S2468-1253(16)30024-3.
    [14]
    AGARWAL K, BRUNETTO M, SETO WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection[J]. J Hepatol, 2018, 68(4): 672-681. DOI: 10.1016/j.jhep.2017.11.039.
    [15]
    LU JH, YANG L, ZHAO ZX, et al. Comparative study of high-sensitivity and conventional fluorescence quantitative PCR in the monitoring of antiviral efficacy in patients with chronic hepatitis B[J]. J Mol Diagn Ther, 2019, 11(5): 361-364. DOI: 10.3969/j.issn.1674-6929.2019.05.005.

    卢建华, 杨莉, 赵召霞, 等. 高敏与普通荧光定量PCR技术在慢乙肝患者抗病毒疗效监测中的对比研究[J]. 分子诊断与治疗杂志, 2019, 11(5): 361-364. DOI: 10.3969/j.issn.1674-6929.2019.05.005.
    [16]
    LEE SB, JEONG J, PARK JH, et al. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir[J]. Clin Mol Hepatol, 2020, 26(3): 364-375. DOI: 10.3350/cmh.2020.0012.
    [17]
    SUN Y, WU X, ZHOU J, et al. Persistent low level of hepatitis B virus promotes fibrosis progression during therapy[J]. Clin Gastroenterol Hepatol, 2020, 18(11): 2582-2591. e6. DOI: 10.1016/j.cgh.2020.03.001.
    [18]
    MAK LY, HUANG Q, WONG DK, et al. Residual HBV DNA and pgrna viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy[J]. J Gastroenterol, 2021, 56(5): 479-488. DOI: 10.1007/s00535-021-01780-5.
    [19]
    KIM SS, HWANG JC, LIM SG, et al. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: Comparison between compensated and decompensated cirrhosis[J]. Am J Gastroenterol, 2014, 109(8): 1223-1233. DOI: 10.1038/ajg.2014.145.
    [20]
    SHIN SK, YIM HJ, KIM JH, et al. Partial virological response after 2 years of entecavir therapy increases the risk of hepatocellular carcinoma in patients with hepatitis B virusassociated cirrhosis[J]. Gut Liver, 2021, 15(3): 430-439. DOI: 10.5009/gnl20074.
    [21]
    LAI CL, WONG D, IP P, et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B[J]. J Hepatol, 2017, 66(2): 275-281. DOI: 10.1016/j.jhep.2016.08.022.
    [22]
    ALLWEISS L, DANDRI M. The role of cccDNA in HBV maintenance[J]. Viruses, 2017, 9(6): 156. DOI: 10.3390/v9060156.
    [23]
    WANG J, HUANG H, LIU Y, et al. HBV genome and life cycle[J]. Adv Exp Med Biol, 2020, 1179: 17-37. DOI: 10.1007/978-981-13-9151-4_2.
    [24]
    KAPOOR R, KOTTILIL S. Strategies to eliminate HBV infection[J]. Future Virol, 2014, 9(6): 565-585. DOI: 10.2217/fvl.14.36.
    [25]
    ZOULIM F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection[J]. Antiviral Res, 2004, 64(1): 1-15. DOI: 10.1016/j.antiviral.2004.07.003.
    [26]
    KARAYIANNIS P. Hepatitis B virus: Old, new and future approaches to antiviral treatment[J]. J Antimicrob Chemother, 2003, 51(4): 761-785. DOI: 10.1093/jac/dkg163.
    [27]
    ZOULIM F. Antiviral therapy of chronic hepatitis B: Can we clear the virus and prevent drug resistance?[J]. Antivir Chem Chemother, 2004, 15(6): 299-305. DOI: 10.1177/095632020401500602.
    [28]
    KIM KH, KIM ND, SEONG BL. Discovery and development of anti-HBV agents and their resistance[J]. Molecules, 2010, 15(9): 5878-5908. DOI: 10.3390/molecules15095878.
    [29]
    DELANEY WE 4th, RAY AS, YANG H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus[J]. Antimicrob Agents Chemother, 2006, 50(7): 2471-2477. DOI: 10.1128/aac.00138-06.
    [30]
    HUANG D, ZHANG YZ, CHEN XG. Analysis on intracellular nucleoside triphosphate levels in normal and tumor cell lines by high-performance liquid chromatography[J]. J Harbin Univ Comm(Nat Sci Edition), 2002, 18(3): 241-247. DOI: 10.3969/j.issn.1672-0946.2002.03.001.

    黄丹, 张亚卓, 陈晓光. 正常细胞及肿瘤细胞内核苷酸库的分析[J]. 哈尔滨商业大学学报(自然科学版), 2002, 18(3): 241-247. DOI: 10.3969/j.issn.1672-0946.2002.03.001.
    [31]
    YANG J. Entecavir's pharmacodynamic characteristics and anti-hepatitis B virus trials[J]. China Pharm, 2015, 26(8): 1150-1152. DOI: 10.6039/j.issn.1001-0408.2015.08.50.

    杨洁. 恩替卡韦的药效学特征及抗乙型肝炎病毒试验荟萃[J]. 中国药房, 2015, 26(8): 1150-1152. DOI: 10.6039/j.issn.1001-0408.2015.08.50.
    [32]
    HIGASHI-KUWATA N, HAYASHI S, KUMAMOTO H, et al. Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV[J]. J Hepatol, 2021, 74(5): 1075-1086. DOI: 10.1016/j.jhep.2020.12.006.
    [33]
    BOYD A, LACOMBE K, LAVOCAT F, et al. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients[J]. J Hepatol, 2016, 65(4): 683-691. DOI: 10.1016/j.jhep.2016.05.014.
    [34]
    KOUMBI L. Current and future antiviral drug therapies of hepatitis B chronic infection[J]. World J Hepatol, 2015, 7(8): 1030-1040. DOI: 10.4254/wjh.v7.i8.1030.
    [35]
    LIU Y, LIU H, HU Z, et al. Hepatitis B virus virions produced under nucleos(t)ide analogue treatment are mainly not infectious because of irreversible DNA chain termination[J]. Hepatology, 2020, 71(2): 463-476. DOI: 10.1002/hep.30844.
    [36]
    GOYAL A, RIBEIRO RM, PERELSON AS. The role of infected cell proliferation in the clearance of acute HBV infection in humans[J]. Viruses, 2017, 9(11): 350. DOI: 10.3390/v9110350.
    [37]
    ALLWEISS L, VOLZ T, GIERSCH K, et al. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo[J]. Gut, 2018, 67(3): 542-552. DOI: 10.1136/gutjnl-2016-312162.
    [38]
    WONG D, LITTLEJOHN M, EDWARDS R, et al. ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B[J]. Liver Int, 2018, 38(10): 1760-1769. DOI: 10.1111/liv.13716.
    [39]
    YAN Y, ALLWEISS L, YANG D, et al. Down-regulation of cell membrane localized NTCP expression in proliferating hepatocytes prevents hepatitis B virus infection[J]. Emerg Microbes Infect, 2019, 8(1): 879-894. DOI: 10.1080/22221751.2019.1625728.
    [40]
    GUAN G, ZHENG L, XI J, et al. Cell cycle arrest protein CDKN2C is not an hbv host factor[J]. Virol Sin, 2021. DOI: 10.1007/s12250-020-00337-9.
    [41]
    YANG RF, CHEN HS, LU FM. New requirements for hepatitis b virus nucleic acid testing in current clinical practice of chronic hepatitis b treatment[J]. Chin J New Clin Med, 2021, 14(1): 1-7. DOI: 10.3969/j.issn.1674-3806.2021.01.01.

    杨瑞锋, 陈红松, 鲁凤民. 当今慢性乙型肝炎治疗实践对HBV核酸检测方法的新需求[J]. 中国临床新医学, 2021, 14(1): 1-7. DOI: 10.3969/j.issn.1674-3806.2021.01.01.
    [42]
    TERRAULT NA, BZOWEJ NH, CHANG KM, et al. AASLD guidelines for treatment of chronic hepatitis B[J]. Hepatology, 2016, 63(1): 261-283. DOI: 10.1002/hep.28156.
    [43]
    TENNEY DJ, ROSE RE, BALDICK CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy[J]. Hepatology, 2009, 49(5): 1503-1514. DOI: 10.1002/hep.22841.
    [44]
    ZOUTENDIJK R, REIJNDERS JG, BROWN A, et al. Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response[J]. Hepatology, 2011, 54(2): 443-451. DOI: 10.1002/hep.24406.
    [45]
    CHO JY, SOHN W, SINN DH, et al. Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: Base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response[J]. Korean J Intern Med, 2017, 32(4): 636-646. DOI: 10.3904/kjim.2016.096.
    [46]
    YIM HJ, KIM IH, SUH SJ, et al. Switching to tenofovir vs continuing entecavir for hepatitis B virus with partial virologic response to entecavir: A randomized controlled trial[J]. J Viral Hepat, 2018, 25(11): 1321-1330. DOI: 10.1111/jvh.12934.
    [47]
    CHEN J, ZHAO SS, LIU XX, et al. Comparison of the efficacy of tenofovir versus tenofovir plus entecavir in the treatment of chronic hepatitis B in patients with poor efficacy of entecavir: A systematic review and meta-analysis[J]. Clin ther, 2017, 39(9): 1870-1880. DOI: 10.1016/j.clinthera.2017.07.015.
    [48]
    WANG YH, LIAO J, ZHANG DM, et al. Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir[J]. J Med Virol, 2020, 92(3): 302-308. DOI: 10.1002/jmv.25608.
    [49]
    CHAUNG KT, O'BRIEN C, HA NB, et al. Alternative therapies for chronic hepatitis B patients with partial virological response to standard entecavir monotherapy[J]. J Clin Gastroenterol, 2016, 50(4): 338-344. DOI: 10.1097/mcg.0000000000000455.
    [50]
    LI ZB, LI L, NIU XX, et al. Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia[J]. Liver Int, 2021. DOI: 10.1111/liv.14786.[Onlineaheadofprint]
    [51]
    HU P, SHANG J, ZHANG WH, et al. HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: New switch study[J]. Chin J Hepatol, 2018, 26(10): 756-764. DOI: 10.3760/cma.j.issn.1007-3418.2018.10.005.

    胡鹏, 尚佳, 张文宏, 等. 核苷(酸)类似物治疗部分应答的乙型肝炎患者通过聚乙二醇干扰素α-2a治疗获得HBsAg消失: New Switch研究[J]. 中华肝脏病杂志, 2018, 26(10): 756-764. DOI: 10.3760/cma.j.issn.1007-3418.2018.10.005.
    [52]
    YEH ML, HUANG JF, YU ML, et al. Hepatitis B infection: Progress in identifying patients most likely to respond to peginterferon alfa[J]. Expert Rev Gastroenterol Hepatol, 2021, 15(4): 427-435. DOI: 10.1080/17474124.2021.1866985.
    [53]
    NING Q, HAN M, SUN Y, et al. Switching from entecavir to pegifn alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial)[J]. J Hepatol, 2014, 61(4): 777-784. DOI: 10.1016/j.jhep.2014.05.044.
    [54]
    HAN M, JIANG J, HOU J, et al. Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-α2a: 1 year follow-up of the OSST study[J]. Antivir Ther, 2016, 21(4): 337-344. DOI: 10.3851/imp3019.
    [55]
    JIN Y, HUANG CY, WEI FL, et al. Combination therapy in HBeAg-positive chronic hepatitis B patients with poor virological response/HBV resistance to NAs[J]. Infect Dis Info, 2015, 28(5): 273-278. DOI: 10.3969/j.issn.1007-8134.2015.05.005.

    金怡, 黄春洋, 魏飞力, 等. 联合治疗策略在应答不佳/耐药HBeAg阳性慢性乙型肝炎患者中的临床研究[J]. 传染病信息, 2015, 28(5): 273-278. DOI: 10.3969/j.issn.1007-8134.2015.05.005.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1960) PDF downloads(443) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return